News Desk, Amar Ujala, New Delhi
Published by: Prashant Kumar
Updated Sat, 05 Jun 2021 08:39 AM IST
The shortage of corona vaccine in India is going to end soon. By the end of the year, half a dozen vaccines will be available in the country. The cost of expensive vaccines available in private hospitals will come down.
– Photo: PTI
hear the news
India is battling the second wave of Corona. Experts believe that the second wave will be at its peak till July-August. However, the peak will come at different times in different states, in the meantime there is a possibility of a third wave. Experts believe that the third wave will wreak havoc in the country in November-December. Children will be affected the most in the third wave. To avoid this, the clinical trial of the vaccine has also started. Here, by the end of the year, 4 more vaccines are expected in the country. Several vaccines are currently in the pipeline. According to media reports, half a dozen vaccines will come in the market. There are currently three vaccines available in the country, out of which two are Made in India Covashield and Covaccine. At the same time, Russia’s Sputnik vaccine is also available now. The Sputnik vaccine will be available in hospitals from the second week of June.
Pune-based Serum Institute of India (SII) is producing the Oxford AstraZeneca vaccine under the name ‘Covishield’, but in addition, it is also producing the protein-based COVID-19 vaccine NVX-CoV2373 under the name ‘CovoVax’. This vaccine has been developed by the American biotechnology company Novovax. Serum Institute’s production of Covovax has already started. As of now, bridging study of Covovax is going on in India. If the Novavax vaccine gets approval for trials abroad, it is expected that SII will also get approval here soon. It is expected to hit the market within two to three months. In December, 20 crore doses will be produced.
Covaccine maker Bharat Biotech is preparing the nasal vaccine. This vaccine will enter the body through the nose. The first trial of the vaccine is underway. It replaces the intranasal vaccine (BBV154). It is very helpful in preparing anti body.
Geneva Biopharmaceuticals based in Pune has developed India’s first mRNA Covid-19 vaccine, called HGC019. The clinical trial of the vaccine has started since last month.